Switch theme
Sign up to access all valuation multiples
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment.
2006
270
LTM Revenue n/a
LTM EBITDA n/a
$12.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Novacyt has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Novacyt achieved revenue of $12.4M and an EBITDA of -$19.6M.
Novacyt expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Novacyt valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $12.4M | n/a | XXX | XXX | XXX |
| Gross Profit | $31.9M | $6.2M | XXX | XXX | XXX |
| Gross Margin | 256% | NaN% | XXX | XXX | XXX |
| EBITDA | -$19.6M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -158% | NaN% | XXX | XXX | XXX |
| Net Profit | -$10.4M | -$27.6M | XXX | XXX | XXX |
| Net Margin | -84% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Novacyt's stock price is EUR 0 (or $1).
Novacyt has current market cap of EUR 34.0M (or $36.6M), and EV of EUR 11.2M (or $12.0M).
See Novacyt trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.0M | $36.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Novacyt has market cap of $36.6M and EV of $12.0M.
Novacyt's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Novacyt's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Novacyt and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $12.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNovacyt's NTM/LTM revenue growth is n/a
Novacyt's revenue per employee for the last fiscal year averaged $46K, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Novacyt's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Novacyt's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Novacyt and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $46K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 42% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 189% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novacyt acquired XXX companies to date.
Last acquisition by Novacyt was XXXXXXXX, XXXXX XXXXX XXXXXX . Novacyt acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Novacyt founded? | Novacyt was founded in 2006. |
| Where is Novacyt headquartered? | Novacyt is headquartered in France. |
| How many employees does Novacyt have? | As of today, Novacyt has 270 employees. |
| Who is the CEO of Novacyt? | Novacyt's CEO is Mr. Lyn Dafydd Rees. |
| Is Novacyt publicy listed? | Yes, Novacyt is a public company listed on PAR. |
| What is the stock symbol of Novacyt? | Novacyt trades under ALNOV ticker. |
| When did Novacyt go public? | Novacyt went public in 2012. |
| Who are competitors of Novacyt? | Similar companies to Novacyt include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Novacyt? | Novacyt's current market cap is $36.6M |
| Is Novacyt profitable? | Yes, Novacyt is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
